GSK Forecasts Higher Sales on Strong Vaccine Performance, Looks to RSV Shot for Future Growth

GSK reported better-than-expected Q2 results and raised its 2022 outlook, crediting strong vaccine sales.
The company's top-selling Shingrix shingles vaccine is driving current growth, while an upcoming RSV vaccine is seen as a key future growth driver.
GSK spun off its consumer health business to Haleon to sharpen focus on vaccines and prescription drugs like HIV treatments.
The RSV vaccine recently gained regulatory approvals and GSK expects its uptake to start slow but accelerate over time.
GSK is forecasting sales growth between 8-10% in 2022, driven by its strong vaccine portfolio.